Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of IV Eptinezumab in Pediatric Migraine
NCT04537429Phase 1Completed
- Sponsor
- Lundbeck
- Start
- Aug 2020
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of eptinezumab in migraine, sponsored by Lundbeck. Primary endpoints: Area under curve (AUC) (0-infinity) eptinezumab and Cmax eptinezumab. Started Aug 2020; status: completed.
02
Drugs
eptinezumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT04537429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04537429.